HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo
The Journal of Infectious Diseases · 12.04.2024 · 229 (4) · 1123-1130
DOI: 10.1093/infdis/jiad507 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 16.11.2023. Verfasst von Paul N Zivich und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Pre-Exposure Prophylaxis, Sexual and Gender Minorities. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Background
While noninferiority of tenofovir alafenamide and emtricitabine (TAF/FTC) as preexposure prophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) has been shown, interest remains in its efficacy relative to placebo. We estimate the efficacy of TAF/FTC PrEP versus placebo for the prevention of HIV infection.
Methods
We used data from the DISCOVER and iPrEx trials to compare TAF/FTC to placebo. DISCOVER was a noninferiority trial conducted from 2016 to 2017. iPrEx was a placebo-controlled trial conducted from 2007 to 2009. Inverse probability weights were used to standardize the iPrEx participants to the distribution of demographics and risk factors in the DISCOVER trial. To check the comparison, we evaluated whether risk of HIV infection in the shared tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) arms was similar.
Results
Notable differences in demographics and risk factors occurred between trials. After standardization, the difference in risk of HIV infection between the TDF/FTC arms was near zero. The risk of HIV with TAF/FTC was 5.8 percentage points lower (95% confidence interval [CI], −2.0% to −9.6%) or 12.5-fold lower (95% CI, .02 to .31) than placebo standardized to the DISCOVER population.
Conclusions
There was a reduction in HIV infection with TAF/FTC versus placebo across 96 weeks of follow-up. Clinical Trials Registration NCT02842086 and NCT00458393.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Institute of Global Health and Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
- Gilead Sciences, Foster City, California, USA.
- Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Paul N Zivich, Jessie K Edwards, David V Glidden, Bonnie E Shook-Sa, Adaora A Adimora, Joseph J Eron
Förderung
- NIAID NIH HHS
- NIH HHS
- NICHD NIH HHS
- National Institute of Allergy and Infectious Diseases
- Division
- of Acquired Immunodeficiency Syndrome
- NIH
- Bill and Melinda Gates Foundation
Zitieren
APA
Zivich, P. N., Cole, S. R., Edwards, J. K., Glidden, D. V., Das, M., Shook-Sa, B. E., Shao, Y., Mehrotra, M. L., Adimora, A. A., & Eron, J. J. (2024). HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo. The Journal of Infectious Diseases, 229(4), 1123-1130. https://doi.org/10.1093/infdis/jiad507
Vancouver
Zivich PN, Cole SR, Edwards JK, Glidden DV, Das M, Shook-Sa BE, et al. HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo. The Journal of Infectious Diseases. 2024;229(4):1123-1130. doi:10.1093/infdis/jiad507
BibTeX
@article{Zivich2024,
author = {Zivich, Paul N and Cole, Stephen R and Edwards, Jessie K and Glidden, David V and Das, Moupali and Shook-Sa, Bonnie E and Shao, Yongwu and Mehrotra, Megha L and Adimora, Adaora A and Eron, Joseph J},
title = {HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo},
journal = {The Journal of Infectious Diseases},
year = {2024},
volume = {229},
number = {4},
pages = {1123--1130},
doi = {10.1093/infdis/jiad507}
}
EUVIMED